Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab

The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is established, but a reliable clinical risk stratification flow-chart is lacking. New risk factors are needed, such as the possible role of the anti-JC polyomavirus (JCPyV) neutralizing antibody. In this pilot...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Viruses
Auteurs principaux: Diotti, Roberta Antonia, Capra, Ruggero, Moiola, Lucia, Caputo, Valeria, De Rossi, Nicola, Sangalli, Francesca, Martinelli, Vittorio, Burioni, Roberto, Clementi, Massimo, Mancini, Nicasio
Format: Artigo
Langue:Inglês
Publié: MDPI 2016
Sujets:
Communication
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4885083/
https://ncbi.nlm.nih.gov/pubmed/27164128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/v8050128
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires